作者
Ta King,Jaclyn P. Lyman,Mithat Gonen,Amy Voci,Camilla Boafo,ES Hwang,HS Rugo,Michael Alvarado,MC Liu,Judy C. Boughey,Lisa K. Jacobs,Helen Krontiras,Kandace P. McGuire,Anna Maria Storniolo,Rita Nanda,Mehra Golshan,Claudine Isaacs,L Bijelic,Ingrid M. Meszoely,C. Van Poznak,Gildy Babiera,Larry Norton,Monica Morrow,EP Winer,Antonio C. Wolff,Clifford A. Hudis
摘要
Background: Retrospective studies suggest that primary breast surgery is associated with improved overall survival (OS) in Stage IV breast cancer. TBCRC 013 is a multi-center prospective registry study evaluating the role of surgery for the primary tumor in Stage IV disease. Methods: From 7/09 - 4/12, 128 eligible pts from 14 sites were enrolled in two cohorts (A: Stage IV with intact primary tumor (n = 112); B: metastases (mets) within 3 months of primary surgery (n = 16)). Baseline patient and tumor characteristics, and surgery of the primary were correlated with 2yr overall survival (OS) using log rank, Kaplan Meier and Cox regression for all patients. Comparisons were also made between cohorts A and B and within cohort A stratified by response to systemic therapy. Responders included those with any response (partial,complete) or stable disease at distant sites. Results: Median pt age was 52yrs(21-79) and median primary tumor size 3.2cm(0.7-15). Phenotypes were ER+ 106 (83%), HER2neg 91(71%), and triple neg 10(8%). 60(47%) had bone-only mets. The only significant baseline difference between cohorts A and B was the presence of palpable nodes (A:62% vs B:0%, p Conclusions: In this prospective registry study, patients diagnosed with mets within 3 months of primary breast surgery have an improved 2yr OS. When all pts having surgery (A + B) are examined, surgery is associated with improved OS on MVA, but when limited to Arm A responders, elective surgery does not improve OS. Given that the number of Arm A responders is small, results from the prospective randomized trial will be needed to address this question. These data also demonstrate that the need for surgical palliation of the primary tumor is uncommon in the modern era. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-18-09.